173 related articles for article (PubMed ID: 28832981)
1. Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee.
Dann EJ; Paltiel O
Br J Haematol; 2018 Oct; 183(1):131-133. PubMed ID: 28832981
[No Abstract] [Full Text] [Related]
2. Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma.
Adams HJA; Kwee TC
Br J Haematol; 2018 Oct; 183(1):129-131. PubMed ID: 28905368
[No Abstract] [Full Text] [Related]
3. Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.
Mesguich C; Cazeau AL; Bouabdallah K; Hindié E
Br J Haematol; 2018 Apr; 181(1):124-125. PubMed ID: 28106255
[No Abstract] [Full Text] [Related]
4. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
Adams HJ; Kwee TC
Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
[TBL] [Abstract][Full Text] [Related]
5. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
6. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
[TBL] [Abstract][Full Text] [Related]
7. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
8. Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee.
Milgrom SA; Pinnix CC; Gunther JR; Fanale M; Dabaja BS
Br J Haematol; 2019 Jan; 184(2):292-293. PubMed ID: 29265334
[No Abstract] [Full Text] [Related]
9. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
10. Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".
Hindié E; Mesguich C; Bouabdallah K; Milpied N
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1937-1939. PubMed ID: 28707119
[No Abstract] [Full Text] [Related]
11. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
Terasawa T; Lau J; Bardet S; Couturier O; Hotta T; Hutchings M; Nihashi T; Nagai H
J Clin Oncol; 2009 Apr; 27(11):1906-14. PubMed ID: 19273713
[TBL] [Abstract][Full Text] [Related]
12. Value of detecting bone marrow involvement in Hodgkin lymphoma - Response to Adams and Kwee.
Pedersen MA; Gormsen LC; d'Amore F
Br J Haematol; 2019 Nov; 187(3):396-397. PubMed ID: 31483478
[No Abstract] [Full Text] [Related]
13. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
Kostakoglu L; Gallamini A
J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
[TBL] [Abstract][Full Text] [Related]
14. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. In Reply to Adams and Kwee.
Simontacchi G; Filippi AR; Ciammella P; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):725-6. PubMed ID: 26461018
[No Abstract] [Full Text] [Related]
15. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
Hutchings M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
Kostakoglu L; Evens AM
Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
[TBL] [Abstract][Full Text] [Related]
17. Early interim PET scan in Hodgkin lymphoma: where do we stand?
Gallamini A; Hutchings M; Avigdor A; Polliack A
Leuk Lymphoma; 2008 Apr; 49(4):659-62. PubMed ID: 18398732
[TBL] [Abstract][Full Text] [Related]
18. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
19. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
20. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]